Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Woodcock's Legacy: CDER Organizational Improvements

Aug 10 2016

• By Derrick Gingery

Woodcock_Janet_1200x675 — • Source: FDA

Related Content

FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections

Nov 25 2013

CDER’s Woodcock Retiring? Rumors Never Go On Furlough

Oct 14 2013

CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal

Oct 02 2015

PDUFA's 'Real-World' Journey Expected To Be Slow Walk

Jul 23 2016

2020 Vision For FDA's Sentinel: 'Systemic' Integration Of Surveillance Looms

Jul 26 2016

Biosimilars Program Could 'Explode,' Woodcock Warns Congress

Feb 04 2016

Orphan Designation Requests To Get Slower Reviews

May 11 2016

Califf Continues Clinical Trial Reform Crusade With Confirmation Vote Pending

Jan 08 2016

PDUFA Negotiations End With Differences To Resolve In Commitment Letter

Mar 07 2016

Patient-Focused Drug Development At 10: Where Does It Go From Here?

Oct 20 2014

Targeted Therapies On FDA’s Orphan Designation Radar

Apr 29 2013

Medtech In Politics: A Look At Republican And Democratic Party Platforms

Aug 04 2016

Next Up, Parkinson's: Coalition Against Major Diseases Moves To Link Neurodegenerative Ailments In Database

Jun 11 2010

Additional Topics

United States Drug Review Clinical Trials Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window